Adeela Kamal - 03 Sep 2026 Form 3 Insider Report for Actinium Pharmaceuticals, Inc. (ATNM)

Reporting relationship: Chief Scientific Officer
Issuer ticker: ATNM
Reported as of: 03 Sep 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 10 Sep 2026, 17:00:03 UTC
Source filing: View source filing
Reporting owner signature: /s/ Adeela Kamal

Key filing fact

Adeela Kamal filed Form 3 for Actinium Pharmaceuticals, Inc. (ATNM) on 10 Sep 2026.

Key facts

This page summarizes Adeela Kamal's Form 3 filing for Actinium Pharmaceuticals, Inc. (ATNM).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Sep 2026, 17:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002153988 Primary reporting owner

Kamal Adeela

Relationship: Chief Scientific Officer
Address: C/O ACTINIUM PHARMACEUTICALS, INC., 100 PARK AVE., 23RD FLOOR, NEW YORK
Signature: /s/ Adeela Kamal
Signature date: 10 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATNM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 213,648
Date: 03 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATNM holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 120,000
Exercise price: $1.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs"). 80,000 of the RSUs vest as follows: 1/3 on September 2, 2027, 1/3 on September 2, 2028, and 1/3 on September 2, 2029. 133,648 of the RSUs vest on September 2, 2029.

Footnote F2

The stock options vest and become exercisable in fifty equal monthly tranches beginning on October 2, 2026.